Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 413256, 9 pages
Clinical Study

Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression

Department of Diagnostic Sciences, UTHSC, Dental Branch, Behavioral and Biomedical Sciences Building, Rm. 5322, Houston, TX 77054, USA

Received 25 October 2011; Accepted 17 January 2012

Academic Editor: Esra Gunduz

Copyright © 2012 Charles F. Streckfus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. The objective of this study was to compare the salivary protein profiles from individuals diagnosed with breast cancer that were either HER2/neu receptor positive or negative. Methods. Two pooled saliva specimens underwent proteomic analysis. One pooled specimen was from women diagnosed with stage IIa HER2/neu-receptor-positive breast cancer patients ( 𝑛 = 1 0 ) and the other was from women diagnosed with stage IIa HER2/neu-receptor-negative cancer patients ( 𝑛 = 1 0 ). The pooled samples were trypsinized and the peptides labeled with iTRAQ reagent. Specimens were analyzed using an LC-MS/MS mass spectrometer. Results. The results yielded approximately 71 differentially expressed proteins in the saliva specimens. There were 34 upregulated proteins and 37 downregulated proteins.